Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Deloitte
Moodys
Farmers Insurance
Fish and Richardson
Dow
Baxter
US Department of Justice

Generated: February 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

« Back to Dashboard

Clinical Trials for Lansoprazole, Amoxicillin And Clarithromycin

Trial ID Title Status Sponsor Phase Summary
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Yokoyama Foundation for Clinical Pharmacology Phase 3 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084 Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Hamamatsu University Phase 3 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00281047 The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy Unknown status Oita University Phase 2/Phase 3 FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
NCT00281047 The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy Unknown status Hamamatsu University Phase 2/Phase 3 FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Lansoprazole, Amoxicillin And Clarithromycin

Condition Name

Condition Name for Lansoprazole, Amoxicillin And Clarithromycin
Intervention Trials
Helicobacter Pylori Infection 6
Gastritis 2
Helicobacter Pylori 2
Dyspepsia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lansoprazole, Amoxicillin And Clarithromycin
Intervention Trials
Helicobacter Infections 9
Gastritis 4
Communicable Diseases 4
Infection 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lansoprazole, Amoxicillin And Clarithromycin

Trials by Country

Trials by Country for Lansoprazole, Amoxicillin And Clarithromycin
Location Trials
Japan 20
Taiwan 4
Korea, Republic of 3
Mexico 2
Honduras 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lansoprazole, Amoxicillin And Clarithromycin

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase Trials
Phase 4 8
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase Trials
Completed 7
Recruiting 6
Unknown status 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lansoprazole, Amoxicillin And Clarithromycin

Sponsor Name

Sponsor Name for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor Trials
National Taiwan University Hospital 3
Hamamatsu University 2
CJ HealthCare Corporation 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor Trials
Other 20
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Medtronic
QuintilesIMS
Covington
Fuji
Queensland Health
Citi
Boehringer Ingelheim
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.